GSK plc (NYSE:GSK) agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. Under the agreement, GSK ...
GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion. By Rebecca Robbins The British drug maker GSK said on Wednesday that it ...
Over the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results